The European Patent Office (EPO) has granted a European Patent to CovalX AG for a new method to characterize the effect of potential drugs on protein-protein interactions

Zürich - June 26th 2012

The European Patent Office (EPO) has granted a European Patent (08717827.3-2404) to CovalX AG for a new method to characterize the effect of potential drugs on protein-protein interaction. The patent is based on the used of CovalX's proprietary technology.

The method of the invention is adapted to high through put analysis and is based on a specially developed cross-linking chemistry and ultra high mass MALDI mass spectrometry. This new method allows a fast and direct analysis of potential therapeutic targeting protein-protein interactions. The method can be applied in most formulation buffers and allows to characterize IC50 of drug candidates. 

 The patented method has been recently implemented in CovalX CRO laboratory and help pharmaceutical and biotechnology companies to evaluate drug candidates.